Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Aurélie Catteau"'
Autor:
Fulong Wang, Shixun Lu, Di Cao, Juanjuan Qian, Cong Li, Rongxin Zhang, Feng Wang, Miaoqing Wu, Yifan Liu, Zhizhong Pan, Xiaojun Wu, Zhenhai Lu, Peirong Ding, Liren Li, Junzhong Lin, Aurélie Catteau, Jérôme Galon, Gong Chen
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTThis study aimed to validate the prognostic value of Immunoscore (IS) in stage II colorectal cancer (CRC), and explore the roles of IS and circulating tumor DNA (ctDNA) in the adjuvant treatment for early-stage CRC. Resected tumor samples fro
Externí odkaz:
https://doaj.org/article/89b95f1a4dbf4a6e976c2cbd1aeac50d
Autor:
François Ghiringhelli, Frederic Bibeau, Laurent Greillier, Jean-David Fumet, Alis Ilie, Florence Monville, Caroline Laugé, Aurélie Catteau, Isabelle Boquet, Amine Majdi, Erwan Morgand, Youssef Oulkhouir, Nicolas Brandone, Julien Adam, Thomas Sbarrato, Alboukadel Kassambara, Jacques Fieschi, Stéphane Garcia, Anne Laure Lepage, Pascale Tomasini, Jérôme Galon
Publikováno v:
EBioMedicine, Vol 92, Iss , Pp 104633- (2023)
Summary: Background: Anti-PD-1 and PD-L1 antibodies (mAbs) are approved immunotherapy agents to treat metastatic non-small cell lung cancer (NSCLC) patients. Only a minority of patients responds to these treatments and biomarkers predicting response
Externí odkaz:
https://doaj.org/article/af4bad0461854aff8dc0c5518a34fcbc
Autor:
Chiara Cremolini, Daniele Rossini, Sara Lonardi, Filippo Pietrantonio, Gianluca Masi, Roberto Moretto, Alessandra Boccaccino, Jerome Galon, Jacques Fieschi, Stefano Tamberi, Gabriella Fontanini, Lisa Salvatore, Clara Ugolini, Alboukadel Kassambara, Emiliano Tamburini, Veronica Conca, Aurélie Catteau, Carlotta Antoniotti, Mirella Giordano, Agnese Proietti, Anello Marcello Poma
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 4 (2023)
Background Tumor immune cells influence the efficacy of immune-checkpoint inhibitors (ICIs) and many efforts aim at identifying features of tumor immune microenvironment able to predict benefit from ICIs in proficient mismatch repair (pMMR)/microsate
Externí odkaz:
https://doaj.org/article/bd3dc2d98d4c4c5d878cb9d38164d9cc
Autor:
Otto Metzger-Filho, Aurélie Catteau, Stefan Michiels, Marc Buyse, Michail Ignatiadis, Kamal S Saini, Evandro de Azambuja, Virginie Fasolo, Sihem Naji, Jean Luc Canon, Paul Delrée, Michel Coibion, Pino Cusumano, Veronique Jossa, Jean Pierre Kains, Denis Larsimont, Vincent Richard, Daniel Faverly, Nathalie Cornez, Peter Vuylsteke, Brigitte Vanderschueren, Hélène Peyro-Saint-Paul, Martine Piccart, Christos Sotiriou
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e66848 (2013)
Genomic Grade Index (GGI) is a 97-gene signature that improves histologic grade (HG) classification in invasive breast carcinoma. In this prospective study we sought to evaluate the feasibility of performing GGI in routine clinical practice and its i
Externí odkaz:
https://doaj.org/article/f2644542bcbd47d9993bd4ae4824c476
Autor:
Carlotta Antoniotti, Alessandra Boccaccino, Robert Seitz, Mirella Giordano, Aurélie Catteau, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Kimberly McGregor, Francesca Bergamo, Veronica Conca, Simone Leonetti, Federica Morano, Giorgio Papiani, Emiliano Tamburini, Maria Bensi, Sabina Murgioni, Douglas Teller Ross, Alessandro Passardi, Isabelle Boquet, Tyler J. Nielsen, Jérôme Galon, Matthew Gordon Varga, Brock L. Schweitzer, Chiara Cremolini
Publikováno v:
Clinical Cancer Research. :OF1-OF8
Purpose: AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc7a8416e2540ffff3da6a3eefd68d91
https://doi.org/10.1158/1078-0432.ccr-22-3878
https://doi.org/10.1158/1078-0432.ccr-22-3878
Autor:
Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, Aurélie Catteau, Lisa Salvatore, Sara Lonardi, Isabelle Boquet, Stefano Tamberi, Federica Marmorino, Roberto Moretto, Margherita Ambrosini, Emiliano Tamburini, Giampaolo Tortora, Alessandro Passardi, Francesca Bergamo, Alboukadel Kassambara, Thomas Sbarrato, Federica Morano, Giuliana Ritorto, Beatrice Borelli, Alessandra Boccaccino, Veronica Conca, Mirella Giordano, Clara Ugolini, Jacques Fieschi, Alexia Papadopulos, Clémentine Massoué, Giuseppe Aprile, Lorenzo Antonuzzo, Fabio Gelsomino, Erika Martinelli, Nicoletta Pella, Gianluca Masi, Gabriella Fontanini, Luca Boni, Jérôme Galon, Chiara Cremolini
Publikováno v:
The Lancet Oncology. 23:876-887
Immune checkpoint inhibitors have not shown clinical benefit to patients with metastatic colorectal cancer who had proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumours in previous studies. Both an active combination chemotherapy (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e319f29a71b733c7203ed171aea9b78
https://doi.org/10.1016/s1470-2045(22)00274-1
https://doi.org/10.1016/s1470-2045(22)00274-1
Autor:
Chiara Cremolini, Brock L. Schweitzer, Matthew Gordon Varga, Jérôme Galon, Tyler J. Nielsen, Isabelle Boquet, Alessandro Passardi, Douglas Teller Ross, Sabina Murgioni, Maria Bensi, Emiliano Tamburini, Giorgio Papiani, Federica Morano, Simone Leonetti, Veronica Conca, Francesca Bergamo, Kimberly McGregor, Lisa Salvatore, Filippo Pietrantonio, Daniele Rossini, Aurélie Catteau, Mirella Giordano, Robert Seitz, Alessandra Boccaccino, Carlotta Antoniotti
Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4332a88187297585a34006d3116e37fa
https://doi.org/10.1158/1078-0432.22692642
https://doi.org/10.1158/1078-0432.22692642
Autor:
Chiara Cremolini, Brock L. Schweitzer, Matthew Gordon Varga, Jérôme Galon, Tyler J. Nielsen, Isabelle Boquet, Alessandro Passardi, Douglas Teller Ross, Sabina Murgioni, Maria Bensi, Emiliano Tamburini, Giorgio Papiani, Federica Morano, Simone Leonetti, Veronica Conca, Francesca Bergamo, Kimberly McGregor, Lisa Salvatore, Filippo Pietrantonio, Daniele Rossini, Aurélie Catteau, Mirella Giordano, Robert Seitz, Alessandra Boccaccino, Carlotta Antoniotti
Purpose:AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9c77aca2057d946a319565137c40acb
https://doi.org/10.1158/1078-0432.c.6615933.v1
https://doi.org/10.1158/1078-0432.c.6615933.v1
Autor:
Chiara Cremolini, Brock L. Schweitzer, Matthew Gordon Varga, Jérôme Galon, Tyler J. Nielsen, Isabelle Boquet, Alessandro Passardi, Douglas Teller Ross, Sabina Murgioni, Maria Bensi, Emiliano Tamburini, Giorgio Papiani, Federica Morano, Simone Leonetti, Veronica Conca, Francesca Bergamo, Kimberly McGregor, Lisa Salvatore, Filippo Pietrantonio, Daniele Rossini, Aurélie Catteau, Mirella Giordano, Robert Seitz, Alessandra Boccaccino, Carlotta Antoniotti
Baseline characteristics of patients according to the predefined and optimized DetermaIO score positivity cut-point in the pMMR tumours group.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50452b50c4a7164dbe128538020db82a
https://doi.org/10.1158/1078-0432.22692633
https://doi.org/10.1158/1078-0432.22692633
Autor:
Roberto Moretto, Daniele Rossini, Aurélie Catteau, Carlotta Antoniotti, Mirella Giordano, Alessandra Boccaccino, Clara Ugolini, Agnese Proietti, Veronica Conca, Alboukadel Kassambara, Filippo Pietrantonio, Lisa Salvatore, Sara Lonardi, Stefano Tamberi, Emiliano Tamburini, Anello Marcello Poma, Jacques Fieschi, Gabriella Fontanini, Gianluca Masi, Jérôme Galon, Chiara Cremolini
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006633
BackgroundTumor immune cells influence the efficacy of immune-checkpoint inhibitors (ICIs) and many efforts aim at identifying features of tumor immune microenvironment able to predict benefit from ICIs in proficient mismatch repair (pMMR)/microsatel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2874c9937814d66a637ba1df5b794e6e
https://doi.org/10.1136/jitc-2022-006633
https://doi.org/10.1136/jitc-2022-006633